share_log

Allarity Therapeutics | DEF 14A: Definitive information statements

Allarity Therapeutics | DEF 14A: Definitive information statements

Allarity Therapeutics | DEF 14A：股東委託書決議
美股SEC公告 ·  07/01 16:50
Moomoo AI 已提取核心訊息
Allarity Therapeutics, Inc. has announced a series of corporate actions and updates, including amendments to its Certificate of Incorporation and Equity Incentive Plan, as well as executive officer changes. The company has proposed amendments to decrease authorized shares from 750,500,000 to 250,500,000 and to limit the liability of directors and officers. These amendments are subject to stockholder approval at the Annual Meeting scheduled for July 26, 2024. Additionally, Allarity has entered into agreements with 3i, LP, including a secured promissory note and a waiver agreement related to a public offering. The company has also reported the termination of Chief Medical Officer Marie Foegh and the appointment of Thomas H. Jensen as Chief Executive Officer. Furthermore, Allarity has adopted a compensation recovery policy subject to clawback or recoupment and has detailed its non-employee director compensation policy, which includes limits on the value of awards and cash compensation.
Allarity Therapeutics, Inc. has announced a series of corporate actions and updates, including amendments to its Certificate of Incorporation and Equity Incentive Plan, as well as executive officer changes. The company has proposed amendments to decrease authorized shares from 750,500,000 to 250,500,000 and to limit the liability of directors and officers. These amendments are subject to stockholder approval at the Annual Meeting scheduled for July 26, 2024. Additionally, Allarity has entered into agreements with 3i, LP, including a secured promissory note and a waiver agreement related to a public offering. The company has also reported the termination of Chief Medical Officer Marie Foegh and the appointment of Thomas H. Jensen as Chief Executive Officer. Furthermore, Allarity has adopted a compensation recovery policy subject to clawback or recoupment and has detailed its non-employee director compensation policy, which includes limits on the value of awards and cash compensation.
Allarity Therapeutics，Inc.已經宣佈了一系列的公司行動和更新，包括修改其公司章程和股權激勵計劃以及執行官更改。公司提議將授權股份從7.5億500萬股減少至2.5億500萬股，並限制董事和高級職員的責任。這些修正案將在2024年7月26日的年度股東大會上提交股東批准。此外，Allarity與3i，LP達成了協議，包括一份擔保的應付票據和與公開發行相關的豁免協議。公司還報告了首席醫療官Marie Foegh的離職和任命Thomas H. Jensen爲首席執行官。此外，Allarity已經採用了一項薪酬恢復政策，受到奪回或收回的限制，並詳細說明了其非僱員董事薪酬政策，其中包括獎勵和現金薪酬價值上限。
Allarity Therapeutics，Inc.已經宣佈了一系列的公司行動和更新，包括修改其公司章程和股權激勵計劃以及執行官更改。公司提議將授權股份從7.5億500萬股減少至2.5億500萬股，並限制董事和高級職員的責任。這些修正案將在2024年7月26日的年度股東大會上提交股東批准。此外，Allarity與3i，LP達成了協議，包括一份擔保的應付票據和與公開發行相關的豁免協議。公司還報告了首席醫療官Marie Foegh的離職和任命Thomas H. Jensen爲首席執行官。此外，Allarity已經採用了一項薪酬恢復政策，受到奪回或收回的限制，並詳細說明了其非僱員董事薪酬政策，其中包括獎勵和現金薪酬價值上限。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息